Category: Joint ventures/collaborations
-
University, Board Maker Partner on Point-of-Care Diagnostics
8 April 2014. Computer scientists in the U.K. at Southampton University and circuit board manufacturer Newbury Electronics Ltd. are designing a device to detect protein indicators for diagnosing diseases at a doctor’s office or clinic rather than sending out samples to a lab for analysis. The three-year project led by Southampton’s Themis Prodromakis, is funded…
-
Daiichi Sankyo, UCSF Partner on Neurodegenerative Disorders
4 April 2014. The pharmaceutical company Daiichi Sankyo in Tokyo and University of California in San Francisco (UCSF) are collaborating on discovering new drugs to treat neurodegenerative conditions such as Alzheimer’s, Parkinson’s, and Creutzfeldt-Jakob disease. While funding amounts were not disclosed, the deal gives Daiichi Sankyo the option to license compounds discovered through the partnership,…
-
Poplar Trees Engineered to Produce More Biofuels, Wood Pulp
3 April 2014. Researchers at the Great Lakes Bioenergy Research Center, a consortium of University of Wisconsin in Madison and Michigan State University in East Lansing, created a genetically modified poplar tree variety with weakened lignin bonds, making it easier to process into commercial biofuels and wood pulp. The team from the labs of Wisconsin’s…
-
Baxter Acquiring Hemophilia Gene-Therapy Biotech Company
3 April 2014. Baxter International, a pharmaceutical and medical products company in Deerfield, Illinois is buying Chatham Therapeutics LLC, a developer of gene therapy to treat hemophilia. Under the agreement, Baxter will acquire outstanding LLC interests in Chatham for $70 million, but future milestone payments are also possible. The acquisition gives Baxter access to all…
-
EMD Serono, Pfizer, Broad Institute Partner on Lupus Markers
1 April 2014. EMD Serono, a subsidiary of the pharmaceutical company Merck in Rockland, Massachusetts, is joining with the drug maker Pfizer and Broad Institute of Harvard and MIT to identify genomic biomarkers of two types of lupus. The research is funded by EMD Serono and Pfizer, but financial aspects of the agreement were not…
-
Novo Nordisk, University Partner on Diabetes in Big Cities
28 March 2014. The pharmaceutical company Novo Nordisk, based in Denmark, and University College London in the U.K. are studying the scope of diabetes in big cities to develop a strategy for attacking the problem, while accounting for the special needs of urban centers. The Cities Changing Diabetes project, which includes Steno Diabetes Center, a…
-
Drug Discovery Consortium Harnesses Sequencing, Big Data
27 March 2014. A collaboration among the pharmaceutical company GlaxoSmithKline, European Bioinformatics Institute, and Wellcome Trust Sanger Institute aims to tap the power of genomic sequencing combined with bioinformatics to boost the success rate of discovering safe and effective medicines. Financial details of the partnership creating the new Centre for Therapeutic Target Validation were not disclosed. The consortium…
-
New Jersey Tech, IT Company to Develop Autism Device
21 March 2014. Engineers at New Jersey Institute of Technology in Newark and WebTeam Corp. in Somerset, New Jersey are designing a device to help children with autism spectrum disorders develop basic educational skills. Financial details of the collaboration were not disclosed, but NJIT and WebTeam will share the intellectual property arising from the project.…
-
Genetics Group, Analytics Firm Collaborate on Diagnostics
19 March 2014. A genetics research center at University of Utah in Salt Lake City and Omicia Inc., a genomic analytics company in Oakland, California are developing systems to make genomic analysis a routine medical diagnostic procedure. The $6 million in funding for the USTAR Center for Genetic Discovery comes from the university and Utah…
-
Janssen, Univ. of Alberta Partner on Diabetes Research
19 March 2014. Janssen Pharmaceutical Companies, a division of Johnson & Johnson, is joining with University of Alberta in Edmonton to fund research on diabetes with commercial potential. The $600,000 fund, with contributions from Janssen and matched by the government of Alberta and Alberta Diabetes Foundation, will support studies on type 1 and type 2…